Scholars Central

Conference abstractPublished 17 Oct 2016

Innovative pharmacological treatment for enhancement of analgesia and prevention of morphine side effects based on a new pharmaceutical composition containing morphine combined with omega-3 fatty acids

Authors: Carlos Horacio Laino

National University of La Rioja, Argentina

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The treatment of acute and chronic severe pain remains a major daily challenge for health professionals in clinical practice. Chronic pain impairs the quality of life, especially of the elderly. With the increase in life expectancy, the development of chronic pain secondary to degenerative diseases or various types of cancer has also increased. Morphine is a potent analgesic mostly used to control pain. However, long term treatment develops several problems, such as loss of analgesic efficacy (tolerance), increased sensitivity to pain (hyperalgesia) and adverse effects like constipation, nausea, vomiting, sedation, drowsiness, pruritus and weight loss. These effects, together with tolerance and hyperalgesia, may require the use of increasingly higher doses to get the same analgesic effect or discontinue its use, which constitutes a failure of the treatment against pain. Also, because morphine has a short analgesic effect, doses should be administered every 4 hours, causing difficulties for the patient. This project describes a technological development with an innovative character, both in its pharmaceutical composition (morphine and omega-3 fatty acids) and in the pharmacological treatment associated with its use. The main advantage of the new pharmaceutical composition and pharmacological treatment lies in the control of pain with a sub-therapeutic dose of morphine which would eliminate or potentially decrease its adverse effects. Other important clinical benefits of using it in terminally ill patients, (such as cancer sufferers) or patients with other types of chronic diseases are the decrease in tolerance to analgesic effect and the reduction in body weight loss and constipation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Carlos Horacio Laino”